Dr. Sparano Discusses Unmet Needs in Metastatic Breast Cancer

Joseph A. Sparano, MD
Published: Monday, Aug 27, 2018



Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

This remains an incurable disease, Sparano says, although there have been significant improvements in clinical outcomes over the last few years. For patients with estrogen receptor-positive, HER2-negative disease, the rise of CDK4/6 inhibitors has dramatically changed the management of that setting. These agents haven


Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

This remains an incurable disease, Sparano says, although there have been significant improvements in clinical outcomes over the last few years. For patients with estrogen receptor-positive, HER2-negative disease, the rise of CDK4/6 inhibitors has dramatically changed the management of that setting. These agents haven



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x